Cure8 research brief
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information that could influence first‑line biologic choices.
Clinicians treating UC, researchers studying comparative effectiveness of biologics, and adult patients (or caregivers) considering first‑line biologic therapy for ulcerative colitis.
This systematic review and meta-analysis compared long-term outcomes of vedolizumab versus infliximab in biologic‑naive ulcerative colitis patients using studies with ≥12 months follow-up.
The pooled evidence (25 studies, mostly observational) found that vedolizumab was associated with better treatment persistence at multiple timepoints, higher likelihood of clinical and endoscopic remission at 12 months, lower hospitalization rates at some timepoints, less need for dose optimization at 12 months, and fewer serious adverse events compared with infliximab.
Most included studies were observational and heterogeneous; the authors advise cautious interpretation and call for prospective randomized comparisons. The review focuses on biologic‑naive UC patients with at least 12 months follow‑up.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to...
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
